Survivin Expression in Atypical Adenomatous Hyperplasia of the Lung

American Journal of Clinical Pathology

Volumn 120, Issue 5, 2003, Pages 712-719

  Nakanishi, Kuniaki ^a   Kawai, Toshiaki ^a   Kumaki, Fumiyuki ^a   Hiroi, Sadayuki ^a   Mukai, Makio ^b   Ikeda, Eiji ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atypical adenomatous hyperplasia; Pulmonary adenocarcinoma; Survivin

Indexed keywords

ANTIBODY; MESSENGER RNA; PROTEIN BCL 2; PROTEIN P53; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ATYPICAL ADENOMATOUS HYPERPLASIA; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NONMUCINOUS BRONCHIOLOALVEOLAR CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

EID: 0242363631     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/GWTN2JTAN6K73YDE     Document Type: Article

References (52)

1. Shimosato Y, Kodama T, Kameya T. Morphogenesis of peripheral type adenocarcinoma of the lungs. In: Shimosato Y, Melamed MR, Nettesheim P, eds. Morphogenesis of Lung Cancer. Vol 1. Boca Raton, FL: CRC Press; 1982:65-89.
2. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural Tumours. 3rd ed. Heidelberg, Germany: Springer-Verlag; 1999:36. World Health Organization International Histological Classification of Tumours.
3. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med. 1990;114:363-368.
4. Pueblitz S, Hieger LR. Expression of p53 and CEA in atypical adenomatous hyperplasia of the lung. Am J Surg Pathol. 1997;21:867-868.
5. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol. 1995;146:876-887.
6. Kitamura H, Kameda Y, Nakamura N, et al. Atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol. 1996;20:553-562.
7. Kerr KM, Carey FA, King G, et al. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J Pathol. 1994;174:249-256.
8. Slebos RJ, Baas IO, Clement MJ, et al. p53 alterations in atypical alveolar hyperplasia of the lung. Hum Pathol. 1998;29:801-808.
9. Mori M, Kaji M, Tezuka F, et al. Comparative ultrastructural study of atypical adenomatous hyperplasia and adenocarcinoma of the human lung. Ultrastruct Pathol. 1998;22:459-466.
10. Yashima K, Litzky LA, Kaiser L, et al. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res. 1997;57:2373-2377.
11. Nakanishi K, Kawai T, Kumaki F, et al. Expression of human telomerase RNA component (hTERC) and telomerase reverse transcriptase (hTERT) mRNA in atypical adenomatous hyperplasia of the lung. Hum Pathol. 2002;33:697-702.
12. Nakayama H, Noguchi M, Tsuchiya R, et al. Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Mod Pathol. 1990;3:314-320.
13. Yokozaki M, Kodama T, Yokose T, et al. Differentiation of atypical adenomatous hyperplasia and adenocarcinoma of the lung by use of DNA ploidy and morphometric analysis. Mod Pathol. 1996;9:1156-1164.
14. Nakanishi K, Horoi S, Kawai T, et al. Argyrophilic nucleolar-organizer region counts and DNA status in bronchioloalveolar epithelial hyperplasia and adenocarcinoma of the lung. Hum Pathol. 1998;29:235-239.
15. Koga T, Hashimoto S, Sugio K, et al. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. Am J Clin Pathol. 2002;117:464-470.
16. Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Am J Pathol. 1997;151:461-470.
17. Hayashi H, Ito T, Yazawa T, et al. Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinoma. J Pathol. 2000;192:26-31.
18. Kurasono Y, Ito T, Kameda Y, et al. Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch. 1998;432:207-215.
19. Ohshima S, Shimizu Y, Takahama M. Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung. Virchows Arch. 1994;424:129-134.
20. Cooper CA, Carby FA, Bubb VJ, et al. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol. 1997;181:401-404.
21. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasia of the human lung. Cancer Res. 1996;56:2224-2228.
22. Niho S, Yokose T, Suzuki K, et al. Monoclonality of atypical adenomatous hyperplasia of the lung. Am J Pathol. 1999;154:249-254.
23. Kitamura H, Kameda Y, Ito T, et al. Atypical adenomatous hyperplasia of the lung. Am J Clin Pathol. 1999;111:610-622.
24. Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the lung: a possible forerunner in the development of adenocarcinoma of the lung. Mod Pathol. 2001;14:72-84.
25. Kitamura H, Kameda Y, Ito T, et al. Cytodifferentiation of atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: immunohistochemical and ultrastructural studies. Virchows Arch. 1997;431:415-424.
26. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
27. Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and iap. Mol Cell Biol. 1994;14:5212-5222.
28. Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79:1327-1333.
29. L and cytochrome c. Mol Cell Biol. 1998;18:608-615.
30. Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300-304.
31. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
32. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152:43-49.
33. Lu C-D, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808-1812.
34. Kawasaki H, Altieri DC, Lu C-D, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071-5074.
35. Chomczyski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
36. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer. 1996;75:2844-2852.
37. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119-125.
38. Chiodino C, Cesinaro AM, Ottani D, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol. 1999;113:415-418.
39. Konno R, Yamakawa H, Utsuonomiya H, et al. Expression of survivin and bcl-2 in the normal human endometrium. Mol Hum Reprod. 2000;6:529-534.
40. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92-95.
41. Sarela AI, Macadam RCA, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000;46:645-650.
42. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
43. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer [letter]. N Engl J Med. 1999;341:452-453.
44. Monzó M, Rosell R, Felip E, et al. A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancer. J Clin Oncol. 1999;17:2100-2104.
45. Kroemer G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614-620.
46. Lu QL, Abel P, Foster CS, et al. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996;27:102-110.
47. Pezzella F, Turley M, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993;329:690-694.
48. Fontanim G, Vignati S, Bigini D, et al. bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71:1003-1007.
49. Ohsaki Y, Toyoshima E, Fujiuchi S, et al. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res. 1996;2:915-920.
50. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer. 1994;73:2900-2904.
51. Bronner MP, Culin C, Reed JC, et al. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol. 1995;146:20-26.
52. Ginsberg D, Mechta F, Yaniv M, et al. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A. 1991;88:9979-9983.